Grace Therapeutics (NASDAQ:GRCE) Posts Earnings Results, Misses Expectations By $0.03 EPS

Grace Therapeutics (NASDAQ:GRCE) released its earnings results on Wednesday. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), Zacks reports.

Grace Therapeutics Stock Up 0.7%

GRCE traded up $0.02 on Thursday, hitting $3.05. The company’s stock had a trading volume of 37,687 shares, compared to its average volume of 65,013. Grace Therapeutics has a 12 month low of $1.75 and a 12 month high of $4.97. The firm has a market cap of $42.18 million, a P/E ratio of -3.55 and a beta of 0.99. The company’s 50 day simple moving average is $3.09 and its 200-day simple moving average is $3.04.

Wall Street Analyst Weigh In

GRCE has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Grace Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.